These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 8861551)

  • 41. Platelet procoagulant activity induced in vivo by muromonab-CD3 infusion in uremic patients.
    Lozano M; Oppenheimer F; Cofan F; Rosinyol L; Mazzara R; Escolar G; Ordinas A
    Thromb Res; 2001 Dec; 104(6):405-11. PubMed ID: 11755950
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
    Cantarovich M; Latter DA; Loertscher R
    Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation. A plea for multicenter immunosuppressive trials.
    Ross DJ; Jordan SC; Nathan SD; Kass RM; Koerner SK
    Chest; 1996 Apr; 109(4):870-3. PubMed ID: 8635362
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical experience with Muromonab-CD3 monoclonal antibody (OKT3) in heart transplantation.
    Macris MP; Frazier OH; Lammermeier D; Radovancevic B; Duncan JM
    J Heart Transplant; 1989; 8(4):281-7. PubMed ID: 2504894
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation--increased morbidity with OKT3.
    Macdonald PS; Mundy J; Keogh AM; Chang VP; Spratt PM
    Transplantation; 1993 Jan; 55(1):110-6. PubMed ID: 8380508
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A
    Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation.
    Shield CF; Jacobs RJ; Wyant S; Das A
    Am J Kidney Dis; 1996 Jun; 27(6):855-64. PubMed ID: 8651251
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overview of transplantation immunology and the pharmacotherapy of adult solid organ transplant recipients: focus on immunosuppression.
    Bush WW
    AACN Clin Issues; 1999 May; 10(2):253-69; quiz 304-6. PubMed ID: 10578712
    [TBL] [Abstract][Full Text] [Related]  

  • 49. OKT3 serum levels as a guide for prophylactic therapy: a pilot study in kidney transplant recipients.
    Abramowicz D; Goldman M; Mat O; Estermans G; Crusiaux A; Vanherweghem JL; De Pauw L; Kinnaert P; Vereerstraeten P
    Transpl Int; 1994 Jul; 7(4):258-63. PubMed ID: 7916925
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Daclizumab: a review of its use in the management of organ transplantation.
    Carswell CI; Plosker GL; Wagstaff AJ
    BioDrugs; 2001; 15(11):745-73. PubMed ID: 11707149
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Two low-dose OKT3 induction regimens following renal transplantation--clinical experience at a single center.
    Oh HK; Provenzano R; Tayeb J; Satmary N; Jones B
    Clin Transplant; 1998 Aug; 12(4):343-7. PubMed ID: 9686329
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-lymphocyte therapy successfully controls late "cholestatic" rejection in pediatric liver transplant recipients.
    Kerkar N; Morotti RA; Iyer K; Arnon R; Miloh T; Sturdevant M; Suchy F; Florman S; Emre S
    Clin Transplant; 2011; 25(6):E584-91. PubMed ID: 21919961
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HLA-DR incompatibility predicts heart transplant rejection independent of immunosuppressive prophylaxis.
    Costanzo-Nordin MR; Fisher SG; O'Sullivan EJ; Johnson M; Heroux A; Kao W; Mullen GM; Radvany R; Robinson J
    J Heart Lung Transplant; 1993; 12(5):779-89. PubMed ID: 8241215
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
    Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
    N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
    [TBL] [Abstract][Full Text] [Related]  

  • 55. OKT3 prophylaxis in kidney transplant recipients: drug monitoring by flow cytometry.
    Cinti P; Cocciolo P; Evangelista B; Orlandini AM; Bruzzone P; Renna Molajoni E; Cortesini R
    Transplant Proc; 1996 Dec; 28(6):3214-6. PubMed ID: 8962245
    [No Abstract]   [Full Text] [Related]  

  • 56. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3.
    Renlund DG; O'Connell JB; Gilbert EM; Hammond ME; Burton NA; Jones KW; Karwande SV; Doty DB; Menlove RL; Herrick CM
    Transplantation; 1989 Apr; 47(4):599-605. PubMed ID: 2523099
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunosuppressive drugs.
    Bowman H; Lennard TW
    Br J Hosp Med; 1992 Nov 4-17; 48(9):570-3, 576-9. PubMed ID: 1282440
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients.
    van Gelder T; Mulder AH; Balk AH; Mochtar B; Hesse CJ; Baan CC; Vaessen LM; Weimar W
    J Heart Lung Transplant; 1995; 14(2):346-50. PubMed ID: 7779855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation.
    Bock HA; Gallati H; Zürcher RM; Bachofen M; Mihatsch MJ; Landmann J; Thiel G
    Transplantation; 1995 Mar; 59(6):830-40. PubMed ID: 7701577
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat).
    Koch A; Daniel V; Dengler TJ; Schnabel PA; Hagl S; Sack FU
    J Heart Lung Transplant; 2005 Jun; 24(6):708-13. PubMed ID: 15949731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.